Bromocriptine should be discontinued if these changes are observed. Monitor patients for orthostatic hypotension and dizziness, particulaly during dose escalation.
Hallucinations associated with bromocriptine appear to be dose-dependent.
Avoid using these drugs together. Phenylpropanolamine combined with bromocriptine may result in hypertension and ventricular tachycardia. Avoid using these drugs together. Dosage adjustments may be required in patients with hepatic disease.